Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation

被引:199
作者
Greenberg, ER
Baron, JA
Karagas, MR
Stukel, TA
Nierenberg, DW
Stevens, MM
Mandel, JS
Haile, RW
机构
[1] DARTMOUTH COLL SCH MED,LEBANON,NH
[2] UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455
[3] UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA
[4] UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90089
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1996年 / 275卷 / 09期
关键词
D O I
10.1001/jama.275.9.699
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To examine the relationship between beta carotene plasma concentration and beta carotene supplementation and risk of death from major disease causes. Design.-Cohort study of plasma concentrations; randomized, controlled clinical trial of supplementation. Setting.-Medical school-affiliated dermatology practices. Patients.-A total of 1188 men and 532 women with mean age of 63.2 years, who had enrolled in a randomized clinical trial of beta carotene supplementation to prevent nonmelanoma skin cancer. Intervention.-Oral beta carotene, 50 mg per day for a median of 4.3 years. Main Outcome Measures.-All-cause mortality and mortality from cardiovascular disease and cancer. Results.-During a median follow-up period of 8.2 years, there were 285 deaths. Persons whose initial plasma beta carotene concentrations were in the highest quartile (>0.52 mu mol/L [27.7 mu g/dL]) had a lower risk of death from all causes (adjusted relative rate [RR], 0.52; 95% confidence interval [CI] 0.44 to 0.87) and from cardiovascular diseases (adjusted RR, 0.57; 95% CI, 0.34 to 0.95) compared with persons with initial concentrations in the lowest quartile (<0.21 mu mol/L [11.2 mu g/dl]). Patients randomly assigned to beta carotene supplementation showed no reduction in relative mortality rates from all causes (adjusted RR, 1.03; 95% CI, 0.82 to 1.30) or from cardiovascular disease (adjusted RR, 1.16; 95% CI, 0.82 to 1.64). There was no evidence of lower mortality following supplementation among patients with initial beta carotene concentrations below the median for the study group. Conclusions.-These analyses provide no support for a strong effect of supplemental beta carotene in reducing mortality from cardiovascular disease or other causes. Although the possibility exists that beta carotene supplementation produces benefits that are too small or too delayed to have been detected in this study, noncausal explanations should be sought for the association between plasma concentrations of beta carotene and diminished risk of death.
引用
收藏
页码:699 / 703
页数:5
相关论文
共 30 条
  • [1] FRUIT, VEGETABLES, AND CANCER PREVENTION - A REVIEW OF THE EPIDEMIOLOGIC EVIDENCE
    BLOCK, G
    PATTERSON, B
    SUBAR, A
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1992, 18 (01): : 1 - 29
  • [2] DIETARY CAROTENES, VITAMIN-C, AND VITAMIN-E AS PROTECTIVE ANTIOXIDANTS IN HUMAN CANCERS
    BYERS, T
    PERRY, G
    [J]. ANNUAL REVIEW OF NUTRITION, 1992, 12 : 139 - 159
  • [3] CAMPBELL DR, 1994, CANCER EPIDEM BIOMAR, V3, P493
  • [4] DIURNAL AND SEASONAL-VARIATION OF 5 CAROTENOIDS MEASURED IN HUMAN SERUM
    CANTILENA, LR
    STUKEL, TA
    GREENBERG, ER
    NANN, S
    NIERENBERG, DW
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1992, 55 (03) : 659 - 663
  • [5] Cox D. R., 1984, ANAL SURVIVAL DATA
  • [6] HEALTH-ASPECTS OF VEGETARIAN DIETS
    DWYER, JT
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1988, 48 (03) : 712 - 738
  • [7] THE ROLE OF BETA-CAROTENE IN THE PREVENTION OF CARDIOVASCULAR-DISEASE
    GAZIANO, JM
    HENNEKENS, CH
    [J]. CAROTENOIDS IN HUMAN HEALTH, 1993, 691 : 148 - 155
  • [8] GERSTER H, 1991, INT J VITAM NUTR RES, V61, P277
  • [9] A CLINICAL-TRIAL OF BETA-CAROTENE TO PREVENT BASAL-CELL AND SQUAMOUS-CELL CANCERS OF THE SKIN
    GREENBERG, ER
    BARON, JA
    STUKEL, TA
    STEVENS, MM
    MANDEL, JS
    SPENCER, SK
    ELIAS, PM
    LOWE, N
    NIERENBERG, DW
    BAYRD, G
    VANCE, JC
    FREEMAN, DH
    CLENDENNING, WE
    KWAN, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (12) : 789 - 795
  • [10] GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153